<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml">

<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="viewport" content="width=device-width, initial-scale=1">

<style type="text/css">
@font-face {
font-family: octicons-link;
src: url(data:font/woff;charset=utf-8;base64,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) format('woff');
}
body {
-webkit-text-size-adjust: 100%;
text-size-adjust: 100%;
color: #333;
font-family: "Helvetica Neue", Helvetica, "Segoe UI", Arial, freesans, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol";
font-size: 16px;
line-height: 1.6;
word-wrap: break-word;
}
a {
background-color: transparent;
}
a:active,
a:hover {
outline: 0;
}
strong {
font-weight: bold;
}
h1 {
font-size: 2em;
margin: 0.67em 0;
}
img {
border: 0;
}
hr {
box-sizing: content-box;
height: 0;
}
pre {
overflow: auto;
}
code,
kbd,
pre {
font-family: monospace, monospace;
font-size: 1em;
}
input {
color: inherit;
font: inherit;
margin: 0;
}
html input[disabled] {
cursor: default;
}
input {
line-height: normal;
}
input[type="checkbox"] {
box-sizing: border-box;
padding: 0;
}
table {
border-collapse: collapse;
border-spacing: 0;
}
td,
th {
padding: 0;
}
* {
box-sizing: border-box;
}
input {
font: 13px / 1.4 Helvetica, arial, nimbussansl, liberationsans, freesans, clean, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol";
}
a {
color: #4078c0;
text-decoration: none;
}
a:hover,
a:active {
text-decoration: underline;
}
hr {
height: 0;
margin: 15px 0;
overflow: hidden;
background: transparent;
border: 0;
border-bottom: 1px solid #ddd;
}
hr:before {
display: table;
content: "";
}
hr:after {
display: table;
clear: both;
content: "";
}
h1,
h2,
h3,
h4,
h5,
h6 {
margin-top: 15px;
margin-bottom: 15px;
line-height: 1.1;
}
h1 {
font-size: 30px;
}
h2 {
font-size: 21px;
}
h3 {
font-size: 16px;
}
h4 {
font-size: 14px;
}
h5 {
font-size: 12px;
}
h6 {
font-size: 11px;
}
blockquote {
margin: 0;
}
ul,
ol {
padding: 0;
margin-top: 0;
margin-bottom: 0;
}
ol ol,
ul ol {
list-style-type: lower-roman;
}
ul ul ol,
ul ol ol,
ol ul ol,
ol ol ol {
list-style-type: lower-alpha;
}
dd {
margin-left: 0;
}
code {
font-family: Consolas, "Liberation Mono", Menlo, Courier, monospace;
font-size: 12px;
}
pre {
margin-top: 0;
margin-bottom: 0;
font: 12px Consolas, "Liberation Mono", Menlo, Courier, monospace;
}
.select::-ms-expand {
opacity: 0;
}
.octicon {
font: normal normal normal 16px/1 octicons-link;
display: inline-block;
text-decoration: none;
text-rendering: auto;
-webkit-font-smoothing: antialiased;
-moz-osx-font-smoothing: grayscale;
-webkit-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.octicon-link:before {
content: '\f05c';
}
.markdown-body:before {
display: table;
content: "";
}
.markdown-body:after {
display: table;
clear: both;
content: "";
}
.markdown-body>*:first-child {
margin-top: 0 !important;
}
.markdown-body>*:last-child {
margin-bottom: 0 !important;
}
a:not([href]) {
color: inherit;
text-decoration: none;
}
.anchor {
display: inline-block;
padding-right: 2px;
margin-left: -18px;
}
.anchor:focus {
outline: none;
}
h1,
h2,
h3,
h4,
h5,
h6 {
margin-top: 1em;
margin-bottom: 16px;
font-weight: bold;
line-height: 1.4;
}
h1 .octicon-link,
h2 .octicon-link,
h3 .octicon-link,
h4 .octicon-link,
h5 .octicon-link,
h6 .octicon-link {
color: #000;
vertical-align: middle;
visibility: hidden;
}
h1:hover .anchor,
h2:hover .anchor,
h3:hover .anchor,
h4:hover .anchor,
h5:hover .anchor,
h6:hover .anchor {
text-decoration: none;
}
h1:hover .anchor .octicon-link,
h2:hover .anchor .octicon-link,
h3:hover .anchor .octicon-link,
h4:hover .anchor .octicon-link,
h5:hover .anchor .octicon-link,
h6:hover .anchor .octicon-link {
visibility: visible;
}
h1 {
padding-bottom: 0.3em;
font-size: 2.25em;
line-height: 1.2;
border-bottom: 1px solid #eee;
}
h1 .anchor {
line-height: 1;
}
h2 {
padding-bottom: 0.3em;
font-size: 1.75em;
line-height: 1.225;
border-bottom: 1px solid #eee;
}
h2 .anchor {
line-height: 1;
}
h3 {
font-size: 1.5em;
line-height: 1.43;
}
h3 .anchor {
line-height: 1.2;
}
h4 {
font-size: 1.25em;
}
h4 .anchor {
line-height: 1.2;
}
h5 {
font-size: 1em;
}
h5 .anchor {
line-height: 1.1;
}
h6 {
font-size: 1em;
color: #777;
}
h6 .anchor {
line-height: 1.1;
}
p,
blockquote,
ul,
ol,
dl,
table,
pre {
margin-top: 0;
margin-bottom: 16px;
}
hr {
height: 4px;
padding: 0;
margin: 16px 0;
background-color: #e7e7e7;
border: 0 none;
}
ul,
ol {
padding-left: 2em;
}
ul ul,
ul ol,
ol ol,
ol ul {
margin-top: 0;
margin-bottom: 0;
}
li>p {
margin-top: 16px;
}
dl {
padding: 0;
}
dl dt {
padding: 0;
margin-top: 16px;
font-size: 1em;
font-style: italic;
font-weight: bold;
}
dl dd {
padding: 0 16px;
margin-bottom: 16px;
}
blockquote {
padding: 0 15px;
color: #777;
border-left: 4px solid #ddd;
}
blockquote>:first-child {
margin-top: 0;
}
blockquote>:last-child {
margin-bottom: 0;
}
table {
display: block;
width: 100%;
overflow: auto;
word-break: normal;
word-break: keep-all;
}
table th {
font-weight: bold;
}
table th,
table td {
padding: 6px 13px;
border: 1px solid #ddd;
}
table tr {
background-color: #fff;
border-top: 1px solid #ccc;
}
table tr:nth-child(2n) {
background-color: #f8f8f8;
}
img {
max-width: 100%;
box-sizing: content-box;
background-color: #fff;
}
code {
padding: 0;
padding-top: 0.2em;
padding-bottom: 0.2em;
margin: 0;
font-size: 85%;
background-color: rgba(0,0,0,0.04);
border-radius: 3px;
}
code:before,
code:after {
letter-spacing: -0.2em;
content: "\00a0";
}
pre>code {
padding: 0;
margin: 0;
font-size: 100%;
word-break: normal;
white-space: pre;
background: transparent;
border: 0;
}
.highlight {
margin-bottom: 16px;
}
.highlight pre,
pre {
padding: 16px;
overflow: auto;
font-size: 85%;
line-height: 1.45;
background-color: #f7f7f7;
border-radius: 3px;
}
.highlight pre {
margin-bottom: 0;
word-break: normal;
}
pre {
word-wrap: normal;
}
pre code {
display: inline;
max-width: initial;
padding: 0;
margin: 0;
overflow: initial;
line-height: inherit;
word-wrap: normal;
background-color: transparent;
border: 0;
}
pre code:before,
pre code:after {
content: normal;
}
kbd {
display: inline-block;
padding: 3px 5px;
font-size: 11px;
line-height: 10px;
color: #555;
vertical-align: middle;
background-color: #fcfcfc;
border: solid 1px #ccc;
border-bottom-color: #bbb;
border-radius: 3px;
box-shadow: inset 0 -1px 0 #bbb;
}
.pl-c {
color: #969896;
}
.pl-c1,
.pl-s .pl-v {
color: #0086b3;
}
.pl-e,
.pl-en {
color: #795da3;
}
.pl-s .pl-s1,
.pl-smi {
color: #333;
}
.pl-ent {
color: #63a35c;
}
.pl-k {
color: #a71d5d;
}
.pl-pds,
.pl-s,
.pl-s .pl-pse .pl-s1,
.pl-sr,
.pl-sr .pl-cce,
.pl-sr .pl-sra,
.pl-sr .pl-sre {
color: #183691;
}
.pl-v {
color: #ed6a43;
}
.pl-id {
color: #b52a1d;
}
.pl-ii {
background-color: #b52a1d;
color: #f8f8f8;
}
.pl-sr .pl-cce {
color: #63a35c;
font-weight: bold;
}
.pl-ml {
color: #693a17;
}
.pl-mh,
.pl-mh .pl-en,
.pl-ms {
color: #1d3e81;
font-weight: bold;
}
.pl-mq {
color: #008080;
}
.pl-mi {
color: #333;
font-style: italic;
}
.pl-mb {
color: #333;
font-weight: bold;
}
.pl-md {
background-color: #ffecec;
color: #bd2c00;
}
.pl-mi1 {
background-color: #eaffea;
color: #55a532;
}
.pl-mdr {
color: #795da3;
font-weight: bold;
}
.pl-mo {
color: #1d3e81;
}
kbd {
display: inline-block;
padding: 3px 5px;
font: 11px Consolas, "Liberation Mono", Menlo, Courier, monospace;
line-height: 10px;
color: #555;
vertical-align: middle;
background-color: #fcfcfc;
border: solid 1px #ccc;
border-bottom-color: #bbb;
border-radius: 3px;
box-shadow: inset 0 -1px 0 #bbb;
}
.task-list-item {
list-style-type: none;
}
.task-list-item+.task-list-item {
margin-top: 3px;
}
.task-list-item input {
margin: 0 0.35em 0.25em -1.6em;
vertical-align: middle;
}
:checked+.radio-label {
z-index: 1;
position: relative;
border-color: #4078c0;
}
.sourceLine {
display: inline-block;
}
code .kw { color: #000000; }
code .dt { color: #ed6a43; }
code .dv { color: #009999; }
code .bn { color: #009999; }
code .fl { color: #009999; }
code .ch { color: #009999; }
code .st { color: #183691; }
code .co { color: #969896; }
code .ot { color: #0086b3; }
code .al { color: #a61717; }
code .fu { color: #63a35c; }
code .er { color: #a61717; background-color: #e3d2d2; }
code .wa { color: #000000; }
code .cn { color: #008080; }
code .sc { color: #008080; }
code .vs { color: #183691; }
code .ss { color: #183691; }
code .im { color: #000000; }
code .va {color: #008080; }
code .cf { color: #000000; }
code .op { color: #000000; }
code .bu { color: #000000; }
code .ex { color: #000000; }
code .pp { color: #999999; }
code .at { color: #008080; }
code .do { color: #969896; }
code .an { color: #008080; }
code .cv { color: #008080; }
code .in { color: #008080; }
</style>
<style>
body {
box-sizing: border-box;
min-width: 200px;
max-width: 980px;
margin: 0 auto;
padding: 45px;
padding-top: 0px;
}
</style>


</head>

<body>

<h1 id="proposal">Proposal</h1>
<h1 id="alzheimers-diseasenew-hope">Alzheimer’s Disease：New Hope</h1>
<p><strong>The group members:</strong></p>
<p>Mia Yu (my2838)</p>
<p>Aiying Huang (ah4167)</p>
<p>Kairui Wang (kw3103)</p>
<p>Yige Bian (yb2591)</p>
<p>Eunice Wang (cw3555)</p>
<h1 id="the-motivation-for-this-project">The motivation for this
project</h1>
<p>Alzheimer’s disease is an irreversible, progressive brain disorder
affecting more than 6.5 million Americans that slowly destroys memory
and thinking skills and, eventually, the ability to carry out simple
tasks. However, existing drugs only treat the symptoms of Alzheimer’s
disease. They do not treat the root cause of the disease and do not slow
down how quickly it gets worse. To date, there hasn’t been a new drug
approved for Alzheimer’s disease in 20 years. This year is an important
year for AD because a breakthrough occurs in AD treatment: two promising
drugs, Leqembi and Donanmab, for treating Alzheimer’s disease bring
fresh hope. Leqembi, the first treatment that shows an unequivocal
slowing of decline in Alzheimer’s disease, is fully approved by FDA in
July 2023. Donanemab is widely expected to be granted full FDA approval
within the next year. These two medications are both with impressive
Phase III clinical trial results. They represent an important
advancement in the ongoing fight to effectively treat Alzheimer’s
disease and could be the beginning of the end of Alzheimer’s
disease.</p>
<h1 id="the-intended-final-products">The intended final products</h1>
<p>Our project culminates in the creation of a comprehensive website
serving as the central hub for all project-related information and
tools. The website will feature:</p>
<p><strong>Homepage Overview:</strong> A welcoming homepage providing a
succinct overview of the project. It will include essential information
such as the project’s objectives, motivation, the initial questions we
aim to address, and a brief intro of our team members. Additionally, a
screencast will offer visitors a guided tour of our project,
encapsulating our journey from conception to realization.</p>
<p><strong>Data Exploration:</strong> A dedicated section for our data
sources and exploratory data analysis (EDA), offering insights into the
foundational data that informs our research and models.</p>
<p>The website will also host a suite of interactive tools,
visualizations and statistical models focusing on three key topics:</p>
<p><strong>Geographical Analysis Tool:</strong> An interactive ‘Shiny’
application that maps the distribution of Alzheimer’s Disease (AD)
patients across the United States, allowing users to identify patterns
and hotspots.</p>
<p><strong>Risk Factor Analysis:</strong> We will develop statistical
models to analyze the risk factors associated with Alzheimer’s Disease,
providing valuable insights into prevention and early detection
strategies.</p>
<p><strong>Clinical Trials analysis:</strong> Alzheimer’s drug
development pipeline. A spotlight on two recently released medications
will give a further comparison of efficacy, side effects, and other
critical metrics, empowering stakeholders with data-driven insights.</p>
<h1 id="the-planned-data-sources">The planned data sources</h1>
<p><strong>Part I Geographical distribution of AD patients across the
US</strong></p>
<p>Alzheimer’s Association. <a href="https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13016">https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13016</a></p>
<p><strong>Part II</strong></p>
<p>Open access series of imaging studies. <a href="https://www.oasis-brains.org/">https://www.oasis-brains.org/</a></p>
<p><strong>Part III Clinical trials of Alzheimer drugs &amp; comparative
analysis of two recently released drugs</strong></p>
<p>ClinicalTrials.gov. <a href="https://clinicaltrials.gov/search?cond=Alzheimer">https://clinicaltrials.gov/search?cond=Alzheimer</a></p>
<p>Journal articles for Phase III study of</p>
<p>Leqembi (<a href="https://www.nejm.org/doi/10.1056/NEJMoa2212948">https://www.nejm.org/doi/10.1056/NEJMoa2212948</a>)</p>
<p>Donanemab (<a href="https://jamanetwork.com/journals/jama/article-abstract/2807533">https://jamanetwork.com/journals/jama/article-abstract/2807533</a>)</p>
<h1 id="the-planned-analyses--visualizations--coding-challenges">The
planned analyses / visualizations / coding challenges</h1>
<p>In this project, we aim to comprehensively analyze the landscape of
Alzheimer’s disease (AD) patients in the United States.</p>
<p>Part 1 involves mapping the geographical distribution of AD patients
across the country using R packages such as ggplot and leaflet.</p>
<p>In Part 2, we will employ data manipulation and analysis tools like
tidyverse, MASS, and various statistical methods including principal
component analysis, cluster analysis, and regression modeling to
identify key factors contributing to the disease’s onset, such as age,
gender, and ethnicity.</p>
<p>Finally, in Part 3, we will perform a comparative analysis of two
recently released drugs targeting Alzheimer’s disease, utilizing
visualization packages like ggplot2 and plotly to create informative
charts and graphics that illustrate the effectiveness and specificity of
these medications.</p>
<h1 id="the-planned-timeline">The planned timeline</h1>
<table>
<thead>
<tr class="header">
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Nov 13-17</td>
<td>Project review meeting</td>
</tr>
<tr class="even">
<td>Nov 18-21</td>
<td>Prepare and build the intended website</td>
</tr>
<tr class="odd">
<td>Nov 27-30</td>
<td>Complete Part I</td>
</tr>
<tr class="even">
<td>Dec 1-4</td>
<td>Complete Part II</td>
</tr>
<tr class="odd">
<td>Dec 5-7</td>
<td>Complete Part III</td>
</tr>
<tr class="even">
<td>Dec 8-9</td>
<td>Review and check the project, complete screencast and peer
assessment</td>
</tr>
</tbody>
</table>

</body>
</html>
